KRT4 Antibody

What is KRT4 and where is it primarily expressed in tissues?

KRT4 (Keratin 4) is a type II cytoskeletal protein that functions as a structural component in epithelial cells. It is predominantly expressed in non-cornifying squamous epithelium, including cornea and transitional epithelium. The protein is also present in certain ciliated pseudo-stratified epithelia and ductal epithelia of various exocrine glands . Understanding KRT4's tissue distribution is crucial when designing experiments to investigate epithelial biology or pathology, as it serves as a specific marker for certain epithelial subtypes. When selecting tissue samples for KRT4 expression studies, researchers should prioritize squamous and transitional epithelial tissues to achieve optimal detection sensitivity.

How do I select the appropriate KRT4 antibody based on my experimental application?

Selecting the appropriate KRT4 antibody requires careful consideration of multiple factors:

• Application compatibility: Determine whether the antibody has been validated for your specific application. For instance:

  • Western Blotting requires antibodies with high specificity to the denatured protein

  • Immunohistochemistry requires antibodies that recognize fixed epitopes

  • Flow cytometry requires antibodies that recognize native epitopes

• Host species: Consider the host species of the antibody in relation to your secondary detection system and to avoid cross-reactivity with your sample species. Mouse monoclonal and rabbit monoclonal options are available .

• Clonality: Monoclonal antibodies (like clone 6B10, KRT4/2804, or 5H5) provide high specificity for a single epitope, while polyclonal antibodies offer broader epitope recognition .

• Target region: Different antibodies target distinct amino acid regions of KRT4. For instance, some antibodies target amino acids 181-292, while others target regions 1-534, which may affect epitope accessibility in your experimental system .

What sample preparation techniques are optimal for KRT4 detection in tissues?

For optimal KRT4 detection in tissues, specific preparation techniques enhance antibody binding and reduce background:

For immunohistochemistry with formalin-fixed, paraffin-embedded (FFPE) tissues:

• Heat-induced epitope retrieval is essential - boil tissue sections in 10mM Citrate Buffer (pH 6.0) for 10-20 minutes

• Allow sections to cool at room temperature for 20 minutes before proceeding with staining

• Use recommended antibody dilutions (typically 1-2 μg/ml for 30 minutes at room temperature)

For immunofluorescence:

• Proper fixation is critical (typically 4% paraformaldehyde)

• Use recommended antibody concentrations (1-2 μg/ml)

• Include appropriate negative controls and counterstains for nuclear visualization

These methods ensure optimal epitope exposure while maintaining tissue morphology, leading to specific staining patterns characteristic of KRT4's distribution in epithelial tissues.

How can I validate the specificity of KRT4 antibodies in my experimental system?

Validating KRT4 antibody specificity requires a multi-faceted approach to ensure reliable experimental results:

• Protein array validation: Evaluate Z-score and S-score metrics from protein array analysis containing full-length human proteins. For example, the KRT4/2804 clone has been validated against arrays containing more than 19,000 full-length human proteins .

• Positive and negative tissue controls: Use tissues known to express or lack KRT4 based on established literature. Non-cornifying squamous epithelium should show positive staining, while tissues without documented KRT4 expression should remain negative .

• Western blot validation: Verify a single band at the expected molecular weight (approximately 67 kDa) .

• Knockdown/knockout validation: If possible, use siRNA knockdown or CRISPR knockout of KRT4 to confirm antibody specificity.

• Cross-reactivity assessment: Test the antibody against related cytokeratins to confirm specificity, particularly important when studying complex epithelial tissues with multiple keratin expression.

These validation steps help discriminate true KRT4 signals from potential cross-reactivity with other cytokeratins, particularly important when studying diseases where keratin expression patterns may be altered.

What are the considerations for multiplexing KRT4 antibodies with other epithelial markers?

Multiplexing KRT4 antibodies with other epithelial markers requires careful experimental design to avoid signal overlap and interference:

• Antibody host species selection: Choose primary antibodies raised in different host species (mouse vs. rabbit) to allow for species-specific secondary antibodies. For example, KRT4/2804 (mouse monoclonal) can be paired with rabbit-derived antibodies against other markers .

• Fluorophore selection: When designing immunofluorescence panels, select fluorophores with minimal spectral overlap:

  • For KRT4 detection with mouse monoclonal antibodies, secondary antibodies conjugated to CF488 have been validated

  • Pair with fluorophores in distinct spectral ranges for other markers

• Sequential staining protocols: Consider sequential rather than simultaneous staining when using antibodies of the same isotype or host species.

• Epitope competition assessment: Validate that antibodies do not compete for spatially adjacent epitopes when targeting multiple cytokeratins.

• Control for antibody cross-reactivity: Include single-stain controls to verify that secondary antibodies do not cross-react with primary antibodies from different species.

This approach enables comprehensive characterization of epithelial subpopulations through co-localization analysis of KRT4 with other markers such as KRT13 (often co-expressed), E-cadherin, or cell proliferation markers.

How should I interpret variations in KRT4 staining patterns across different tissue pathologies?

Interpreting variations in KRT4 staining patterns across different pathologies requires an understanding of normal expression patterns and systematic analysis:

• Normal baseline establishment: In healthy tissues, KRT4 is expressed in non-cornifying squamous epithelium, cornea, and transitional epithelium . This serves as the reference point for pathological alterations.

• Pattern analysis framework:

  • Subcellular localization (cytoplasmic vs. membrane vs. nuclear)

  • Distribution within tissue layers (basal vs. suprabasal vs. superficial)

  • Intensity variations (loss, reduction, or overexpression)

  • Heterogeneity within tissue regions

• Common pathological alterations:

  • Squamous metaplasia may show altered KRT4 expression

  • Epithelial dysplasia often demonstrates disrupted keratin expression patterns

  • Carcinomas may show loss or abnormal expression of KRT4

• Quantification approaches:

  • H-score methodology for semi-quantitative assessment

  • Digital image analysis for objective quantification of staining intensity and distribution

When interpreting results, consider that changes in KRT4 expression may reflect altered cellular differentiation states, which can be informative for understanding disease mechanisms and progression in epithelial pathologies.

What are the optimal protocols for KRT4 detection by immunohistochemistry?

Optimized immunohistochemistry protocols for KRT4 detection require attention to specific technical parameters:

• Tissue preparation:

  • Formalin fixation (10% neutral buffered formalin for 24-48 hours)

  • Paraffin embedding using standard protocols

  • Section thickness: 4-5 μm is optimal for epithelial tissue visualization

• Antigen retrieval:

  • Heat-induced epitope retrieval in 10mM citrate buffer (pH 6.0)

  • Boil for 10-20 minutes followed by 20-minute cooling at room temperature

• Blocking and antibody incubation:

  • Block endogenous peroxidase (3% H₂O₂, 10 minutes)

  • Protein blocking (5% normal serum, 30 minutes)

  • Primary antibody incubation: KRT4 antibody at 1-2 μg/ml for 30 minutes at room temperature or overnight at 4°C

  • Secondary antibody: HRP-conjugated anti-mouse or anti-rabbit IgG (depending on primary antibody host)

• Detection system:

  • DAB (3,3'-diaminobenzidine) chromogen development (3-5 minutes, monitor microscopically)

  • Counterstain with hematoxylin (30-60 seconds)

  • Dehydration and mounting with permanent mounting medium

These parameters have been validated for clones such as KRT4/2804 and 6B10, demonstrating specific staining of epithelial tissues with minimal background .

How can I optimize flow cytometry protocols for KRT4 detection in cell suspensions?

Optimizing flow cytometry for KRT4 detection presents unique challenges as KRT4 is an intracellular cytoskeletal protein:

• Cell preparation and fixation:

  • Single-cell suspensions obtained through gentle enzymatic dissociation

  • Fixation with 4% paraformaldehyde (10 minutes at room temperature)

  • Permeabilization with 0.1% Triton X-100 or commercial permeabilization buffer

• Antibody staining:

  • Block with 5% serum in PBS (30 minutes)

  • Primary KRT4 antibody: 1-2 μg per million cells

  • Validated clones include KRT4/2804 for flow cytometry applications

  • Incubate for 45-60 minutes at room temperature

  • Secondary antibody (if unconjugated primary): anti-mouse IgG-CF488 or similar fluorophore

• Controls and gating strategy:

  • Include isotype controls (Mouse IgG1 for KRT4/2804 clone)

  • Additional controls: unstained cells, secondary-only controls

  • Gating strategy: exclude debris and doublets before analyzing KRT4 expression

• Data analysis considerations:

  • Measure median fluorescence intensity rather than percent positive cells

  • Consider co-staining with epithelial markers (EpCAM) to identify epithelial populations

This approach has been validated for cell lines such as HeLa and A549, with successful detection of KRT4-positive populations using antibody clone KRT4/2804 .

What troubleshooting approaches should I use for non-specific staining with KRT4 antibodies?

Non-specific staining with KRT4 antibodies can be addressed through systematic troubleshooting:

• Background reduction strategies:

  • Increase blocking time and concentration (use 5-10% serum from the same species as the secondary antibody)

  • Include 0.1-0.3% Triton X-100 in blocking buffer to reduce hydrophobic interactions

  • Add 0.1-0.5M NaCl to antibody diluent to decrease ionic interactions

  • Pre-absorb secondary antibodies with tissue powder from the species being examined

• Antibody optimization:

  • Titrate primary antibody concentration (test range from 0.5-5 μg/ml)

  • Reduce incubation time or temperature

  • Switch to more specific monoclonal antibodies (consider KRT4/2804 or 6B10 clones)

  • Test carrier-free formulations if buffer components are suspected of causing interference

• Protocol modifications:

  • Adjust antigen retrieval conditions (time, temperature, buffer pH)

  • Wash more extensively between steps

  • Use specialized detection systems with lower background

• Technical considerations:

  • Ensure proper tissue fixation (overfixation can increase background)

  • Use freshly prepared reagents

  • Maintain consistent temperature during incubation steps

By systematically implementing these approaches, researchers can significantly improve signal-to-noise ratio and obtain clear, specific KRT4 staining in their experimental systems.

How can KRT4 antibodies be used to investigate epithelial differentiation?

KRT4 antibodies serve as powerful tools for investigating epithelial differentiation due to the precise expression pattern of KRT4 in specific differentiation states:

• Developmental biology applications:

  • Track squamous epithelial differentiation during embryonic development

  • Monitor stratification processes in epithelial tissues

  • Identify commitment to non-cornifying squamous epithelial lineages

• Differentiation marker analysis:

  • KRT4 expression correlates with intermediate to superficial differentiation in stratified epithelia

  • Co-staining with basal markers (KRT5/14) and other differentiation markers (KRT13) creates comprehensive differentiation maps

  • Quantitative analysis of expression gradients provides metrics of differentiation state

• In vitro differentiation models:

  • Monitor successful differentiation of epithelial stem cells toward mucosal phenotypes

  • Validate organoid models for correct epithelial stratification

  • Assess the impact of differentiation-inducing agents on epithelial cultures

• Methodological approach:

  • Use immunofluorescence with antibodies like KRT4/2804 (1-2 μg/ml)

  • Implement digital image analysis to quantify expression levels across tissue layers

  • Correlate with functional assessments of epithelial barrier formation

This approach provides insights into normal differentiation processes and how they may be disrupted in diseases affecting epithelial tissues.

What is the significance of KRT4 expression in cancer research and diagnostics?

KRT4 expression analysis using specific antibodies has significant implications in cancer research and diagnostics:

• Diagnostic applications:

  • Distinguishing tumor subtypes based on differentiation patterns

  • Identifying metaplastic changes in pre-malignant conditions

  • Determining cell of origin in poorly differentiated carcinomas

• Prognostic significance:

  • Altered KRT4 expression may correlate with tumor grade and aggressiveness

  • Expression patterns can indicate differentiation status, which often correlates with clinical outcomes

  • Quantitative assessment using standardized IHC protocols with antibodies such as clone 6B10 or KRT4/2804

• Research applications:

  • Study mechanisms of squamous differentiation in carcinogenesis

  • Investigate epithelial-mesenchymal transition through changes in keratin expression profiles

  • Identify potential therapeutic targets based on differentiation status

• Methodological considerations:

  • Use multiplexed immunohistochemistry to correlate KRT4 with other diagnostic markers

  • Implement digital pathology for quantitative assessment of expression patterns

  • Standardize protocols using validated antibodies at recommended dilutions (1:50-1:200 for IHC-P)

Understanding KRT4 expression in neoplastic tissues provides valuable insights into tumor biology and can guide therapeutic strategies targeting differentiation pathways in cancer.

How do you quantitatively analyze KRT4 expression in immunohistochemistry studies?

Quantitative analysis of KRT4 expression in immunohistochemistry studies requires standardized approaches to ensure reproducibility and meaningful interpretation:

• Semi-quantitative scoring methods:

  • H-score system: Intensity (0-3) × percentage of positive cells (0-100), yielding scores from 0-300

  • Quick-score method: Combines intensity and proportion in a simpler algorithm

  • These methods can be applied to KRT4 staining performed with validated antibodies at recommended concentrations (1-2 μg/ml)

• Digital image analysis approaches:

  • Whole slide imaging followed by computational analysis

  • Segmentation algorithms to identify epithelial regions

  • Intensity thresholding to distinguish positive from negative cells

  • Spatial distribution analysis to evaluate expression across tissue layers

• Standardization considerations:

  • Include reference standards on each slide

  • Use consistent staining protocols and image acquisition parameters

  • Apply color deconvolution algorithms to separate DAB signal from hematoxylin

  • Normalize measurements to control for batch variation

• Advanced analytical methods:

  • Machine learning algorithms for pattern recognition

  • Multiplex analysis correlating KRT4 with other markers

  • 3D reconstruction from serial sections to understand spatial distribution

These quantitative approaches transform descriptive histology into objective metrics that can be statistically analyzed across experimental conditions or patient cohorts.

How can KRT4 antibodies be utilized in single-cell analysis technologies?

KRT4 antibodies can be integrated into cutting-edge single-cell analysis platforms to provide deeper insights into epithelial heterogeneity:

• Single-cell flow cytometry applications:

  • Index sorting of KRT4-positive cells for downstream molecular analysis

  • Using validated antibodies at 1-2 μg per million cells concentration

  • Compatible with antibody clones such as KRT4/2804 that are validated for flow cytometry

• Mass cytometry (CyTOF) integration:

  • Metal-conjugated KRT4 antibodies for high-dimensional phenotyping

  • Simultaneous analysis of multiple differentiation markers at single-cell resolution

  • Spatial analysis through imaging mass cytometry in tissue sections

• Single-cell sequencing enrichment:

  • FACS isolation of KRT4-positive cell populations for targeted single-cell RNA-seq

  • Correlation of transcriptomic profiles with KRT4 protein expression

  • Identification of novel subtypes within KRT4-expressing epithelial populations

• Spatial transcriptomics applications:

  • Antibody-based spatial transcriptomics to correlate KRT4 protein expression with local gene expression profiles

  • Mapping epithelial differentiation trajectories in complex tissues

These emerging technologies allow researchers to move beyond bulk analysis and understand the specific roles of KRT4-expressing cells within heterogeneous tissues, providing unprecedented insights into epithelial biology and pathology.

What are the considerations for using KRT4 antibodies in cross-species studies?

Using KRT4 antibodies in cross-species studies requires careful attention to sequence conservation and validation across target species:

• Cross-reactivity analysis:

  • Several KRT4 antibodies demonstrate validated cross-reactivity across species:

    • Clone 6B10 shows reactivity with human, dog, cat, and zebrafish KRT4

    • Some antibodies react with human, mouse, and rat KRT4

  • Sequence alignment assessment between target species should inform antibody selection

• Species-specific validation requirements:

  • Western blot confirmation of correct molecular weight in each species

  • Immunohistochemistry on known positive tissues from each target species

  • Negative controls from species lacking KRT4 expression in specific tissues

• Epitope conservation considerations:

  • Target epitope regions differ between antibodies (e.g., AA 181-292, 1-534, 386-415)

  • Sequence conservation analysis of these specific regions across species

  • Potential need for species-specific antibodies if epitope conservation is poor

• Protocol modifications:

  • Species-specific antigen retrieval optimization

  • Adjusted antibody concentrations for different species

  • Species-appropriate blocking reagents to prevent non-specific binding

This systematic approach ensures reliable cross-species comparisons, enabling evolutionary studies of epithelial differentiation and comparative research across model organisms.

How can I implement KRT4 antibodies in high-throughput screening applications?

Implementing KRT4 antibodies in high-throughput screening requires specialized approaches to maximize efficiency while maintaining data quality:

• Automated immunostaining platforms:

  • Validation of KRT4 antibodies on automated staining systems

  • Optimization of antibody concentration (typically 1-2 μg/ml) for automated dispensing

  • Quality control measures for consistent staining across large sample batches

• Tissue microarray applications:

  • Construction of TMAs with multiple tissue cores per sample

  • Single-staining run with KRT4 antibodies across hundreds of samples

  • Standardized image acquisition and analysis protocols

• High-content imaging strategies:

  • Multiplexed fluorescent detection of KRT4 with other markers

  • Automated image acquisition of multiple fields per sample

  • Machine learning algorithms for pattern recognition and classification

• Drug screening applications:

  • KRT4 as a differentiation readout in compound screening

  • Automated quantification of expression changes in response to treatment

  • Correlation with other epithelial phenotypic markers

• Data management considerations:

  • Integrated databases linking imaging data with experimental conditions

  • Standardized ontologies for describing epithelial differentiation states

  • Quality control metrics and statistical analysis pipelines

This approach enables large-scale studies of epithelial differentiation in disease models or drug discovery applications while maintaining the specificity and sensitivity offered by validated KRT4 antibodies.